Cohen, S. B., Radominski, S. C., Kameda, H., Kivitz, A. J., Tee, M., Cronenberger, C., . . . Alten, R. (2020). Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial. BioDrugs.
シカゴスタイル引用形Cohen, Stanley B., et al. "Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients With Rheumatoid Arthritis After Switching From Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial." BioDrugs 2020.
MLA引用形式Cohen, Stanley B., et al. "Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients With Rheumatoid Arthritis After Switching From Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial." BioDrugs 2020.